Monopar Therapeutics Said Both Patients Treated To Date At The 650 mg/m2 Dose In Phase1B Study Experienced Tumor Size Reductions – Of 18% And 20% Respectively – After The First Two Cycles Of Camsirubicin Treatment
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics reported that both patients treated in the Phase 1B study at the 650 mg/m2 dose experienced tumor size reductions of 18% and 20% respectively after the first two cycles of Camsirubicin treatment. The patients are set to receive additional cycles of treatment, which may result in further tumor size reduction.
August 08, 2023 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Monopar Therapeutics' successful initial results from the Phase 1B study of Camsirubicin treatment could potentially boost investor confidence and positively impact the company's stock price.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given that the results are from a Phase 1B study, it's still early in the drug development process, but the initial success is promising.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100